www.StockMarketingInc.com: Our Members Know First!! PSGI-"Prime Star Group Introduces Delizia Limited Cigars" Sign Up Today!!

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: PSGI - Prime Star Group, Inc.)

LATEST NEWS!!

Prime Star Group Introduces Delizia Limited Cigars

LAS VEGAS, NV, Nov 12, 2009 -- Prime Star Group, Inc. (OTCBB: PSGI | Quote | Chart | News | PowerRating) is pleased to announce that Delizia Limited, its wholly owned subsidiary, is launching a line of impeccably constructed premium long filler cigars. Prime Star Group's Delizia Limited can produce between 250,000 to 400,000 cigars per month.

The company produces multiple sizes of premium cigars and focuses on the following: -- Connecticut Cigar Size 8 - Churchill, Toro, Robusto, Torpedo, Petite Corona, Lancero, Lonsdale -- Corojo Cigar Size 7 - Churchill, Toro, Robusto, Lonsdale, Torpedo, Lancero -- Habano 2000 Size 7 - Churchill, Toro, Robusto, Torpedo, Lancero, Lonsdale

Roger Mohlman, President of Prime Star Group, stated, "Our Delizia business unit provides Prime Star Group with tremendous opportunity where the consumer seeks premium quality product at an affordable price point. The company remains focused on providing high end products and services that deliver top line and bottom line profitability." About Prime Star Group Prime Star Group, Inc. is a holding company that focuses on four areas of business: SmartPax(TM) Packaging, Premium Food & Beverage Products, and Distribution. The company's operating subsidiaries produce, market, and distribute wines, tea, adult mixed beverages, flavored water, and gourmet seafood products. The company also produces co-brand and co-pack existing high-end beverages and private label liquors for large hospitality and entertainment brands. Prime Star is focused on the food and beverage, entertainment, hospitality, healthcare and disaster relief industries.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(PINKSHEETS: MNDP - Mundus Group, Inc.)

LATEST NEWS!! Mundus Group, Inc. Announces the Formation of AirStar Geo Logic (AGL)

A new division to provide services to natural gas, oil and mining industries by using its subsidiary's technology.

LOS ANGELES, Nov. 12 -- AGL will provide UAV Aerial Imagery & Data collection technologies to geological survey companies in search of natural resources in the mining of minerals, gemstones, precious metals and natural gas & oil industries.

AGL technology has a small footprint for the environment aerial non-disruptive technologies, and also provides increased accuracy that can locate resources and environmental dangers.

AGL provides remote controlled UAVs with GPS technology that, when configured with imagery technology, has the ability to: - track specific positions with large scale area seismic imagery ground sweeps; - hovering in one place; - track the topographical features while descending into difficult locations; and - offer real time views of seismic, optical, infrared and photographic onboard cameras for inspection of ground and structural makeup.

These abilities, while locking on an exact position, provide the collection of extremely valuable information with undisputable imagery resolution improvements. The ability to provide a focused detailing of ground stratification characteristics of fault lines around cliffs and ridges provide an enhanced 3-Dimensional model that far surpasses the predictive accuracy that can be obtained from any fixed wing survey.

AirStar manufactures UAV delivery platforms, as well as sells, services and provides training. AGL provide aerial photography packages, which will out-perform manned aircraft and helicopters for a fraction of the cost and provide strategic advantages to engineers in the search for natural gas, oil and mining as well as the building of bridges, roads and infrastructure in mountainous and hilly areas where fixed wing seismic surveys cannot provide the details that AirStar's hovering UAVs can provide.

AGL was formed to professionally service the geological, mining and natural resource industries with many calls over the past 15 years from engineering firms seeking assistance with detailed aerial analysis of construction sites, engineering projects, mining and natural gas and oil industries.

AGL is one of a family of niche UAV applications identified by Mundus as a unique division to be exploited and targeted for growth by expanding AirStar's capacity and ability to focus on each distinct market. Please see our website for our diverse UAV applications.

AirStar's proprietary CamCopters are famous for their major Hollywood films, commercials and documentaries and also provides a range of preconfigured camera ships that will fit into different budgets. We also offer assistance to the remote control operators who want to take their business to the next level with Aerial Photography of resorts, golf courses, sport events and other innovative aerial photography solutions that will generate revenue streams to their business.

About The Mundus Group, Inc.

The Mundus Group, Inc. (MNDP) is an advanced aerospace technology consortium providing patented Vertical Take Off and Landing (VTOL) technology for experimental aircraft and Unmanned Air Vehicles (UAV) since 1990 through its fully owned VTOL division, Roadable Aircraft International (RAI). Mundus is at the cutting edge of jet turbine-ducted fan technology and fuses state of the art design engineering and a prototyping facility with computer assisted auto flight technologies, Remote Controlled (RC) and composite technologies industry segments. From US Navy co-developed UAVs for aerial observation and environmental testing to advanced VTOL aerospace technology for civilian and military uses, Mundus Group, Inc. is developing revolutionary products with global potential for change that offers economic protection and growth opportunities for investors.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(PINKSHEETS: ONCP - 141 Capital, Inc.)

LATEST NEWS!!

141 Capital's Principals Return Shares

CHICAGO, Nov 12, 2009 -- 141 Capital, Inc. (OTCPK: ONCP).

141 Capital announced today that its CEO, Errol Stone, and Paul D. Strickland, Jr., a director, have collectively contributed 310,000,000 shares of 141 Capital stock to the Company. The shares will be returned to 141's treasury.

Errol Stone, CEO stated: "We are pleased to make this contribution of 310,000,000 shares. It represents tangible value to our shareholders as it substantially reduces the issued and outstanding shares of the Company's common stock." About 141 Capital, Inc. (www.141capital.net) 141 Capital, Inc., is a publicly traded company based in Chicago. Its primary operations involve commodity trading for its own account utilizing trading systems for trading financial products listed on the world's derivatives exchanges. 141 Capital encourages its shareholders to email any and all questions and suggestions. We usually respond to questions after business hours and understand it may take several days to receive a response. Email: info@141capital.net.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: ACTC - Advanced Cell Technology, Inc.)

LATEST NEWS!!

Advanced Cell Technology's Chief Scientific Officer, Robert Lanza, Opening Plenary Speaker at the '3rd International Conference on Cell Therapy'

WORCESTER, Mass., Nov 12, 2009 -- Advanced Cell Technology's (OTCBB: ACTC | Quote | Chart | News | PowerRating) Chief Scientific Officer, Robert Lanza, M.D., will be delivering an opening Plenary Lecture at the '3rd International Conference on Cell Therapy', which will be held in Seoul, South Korea, on November 12, 2009. The Conference will focus on the gap between the bench and bedside, and will include sessions on 'Tissue Specific Stem Cell Therapy', 'Cancer Immune Cell Therapy', 'Cell Therapy for Diabetes' and 'Regenerative Medicine.' Dr. Lanza will be delivering a presentation titled "Embryonic and Induced Pluripotent Stem Cells - Moving from the Bench to the Bedside." During the presentation, Dr. Lanza is expected to discuss the company's various preclinical programs, including its retinal pigment epithelium (RPE) technology, which the Company plans to file an Investigation New Drug (IND) application this quarter to begin human clinical trials. After his presentation, Dr. Lanza will Chair the morning Plenary Session and Panel.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com..

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: SMID - Smith-Midland Corp.)

LATEST NEWS!!

SMC Announces Financial Results for the Quarter Ended September 30, 2009

MIDLAND, Va., Nov 12, 2009 -- Smith-Midland Corporation (OTCBB: SMID | Quote | Chart | News | PowerRating) announced total revenue of $7.6 million for the quarter ended September 30, 2009, compared to $7.8 million for the same period in 2008, a decrease of 3%. Pre-tax earnings for the period were approximately $763,000, compared to approximately $97,000 for the same period in 2008. This represents an increase in pre-tax earnings of approximately $666,000 or 687% over the same three month period in 2008. Net income for the period was approximately $491,000, or $.10 per share (fully diluted), compared to net income of approximately $26,000, or $.01 per share (fully diluted) for the same period in 2008.

Revenues for the nine months ended September 30, 2009 were $24.3 million compared to $21.5 million for the same period in 2008, an increase of 13%. Pre-tax earnings for the nine month period were $3.5 million, compared to approximately $529,000 for the same period in 2008. This represents an increase in pre-tax earnings of $3.0 million, or 567% over the same nine month period in 2008. Net income for the period was approximately $2.1 million, or $.45 per share (fully diluted), compared to net income of approximately $277,000, or $.06 per share (fully diluted) for the same period in 2008.

Rodney I. Smith, Smith-Midland's Chairman and CEO, said, "We at Smith-Midland are extremely pleased with the results of operations for the first three quarters of 2009. The improved profitability for the year is the result of a company wide effort to contain costs, improve efficiency and a focus on providing each customer a quality product delivered in a timely manner. While the profitability of the first three quarters has been remarkably positive, a temporary delay in the start of a major highway contract previously awarded to Smith-Midland will result in lower earnings for the fourth quarter of 2009." Smith-Midland develops, manufactures, licenses, rents, and sells a broad array of precast concrete products for use primarily in the construction, transportation and utilities industries.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: VIVK - Vivakor Inc.)

LATEST NEWS!!

Vivakor Presents at Nutraceutical Event

CORALVILLE, Iowa, Nov 12, 2009 -- Vivakor, Inc. (OTC Bulletin Board: VIVK | Quote | Chart | News | PowerRating) is the keynote presenting company at the founders' celebration of consumer product specialist, Regeneca International, Inc. (www.regeneca.com). The celebration will be attended by over 200 founders and guests of Regeneca International from across the United States. It will be hosted at the prestigious Balboa Bay Club in Newport Beach, California. Vivakor's Chairman, Matt Nicosia and CFO, Ed Corrente will both be attending the event.

Event attendee, Dr. Brian Scott , a Regeneca advisory board member and nationally recognized wellness expert, was particularly pleased to learn of Vivakor's role in the event. "As a healthcare provider and speaker on issues regarding wellness and longevity, it is refreshing to hear the perspective of a company, doing business internationally, which can provide a particular focus on products which extend the length and quality of a person's life." The purpose of the event is to introduce Regeneca's new product offerings that are to be released in the coming months, most significantly, the new nutraceutical formulation developed by Vivakor." About Vivakor, Inc.

Vivakor, Inc. is a transdisciplinary research company that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds. Vivakor also provides contract research services for third parties.

Vivakor's business model is to be a research hub focused on areas that have both an identified scientific need and a substantial market opportunity with a significant market. This approach is intended to provide the necessary environment of transdisciplinary collaboration and cross-pollination to advance research and technology acquisition. Vivakor's mission is to advance or acquire distinct intellectual property and technologies that improve the quality of life for individual patients, researchers, clinicians and consumers. Vivakor believes that the development and commercialization of substantive technologies and cures for complex human conditions, illnesses and diseases require a sophisticated approach with contribution from many areas of business and scientific expertise. Vivakor's research and the technology it acquires are anchored by its relationship with collaborative partners and product-specific commercialization strategies. From the commencement of product conception or acquisition, through development and commercialization, the Company expects to have collaborative partners or licensing arrangements in place for each of its products. Vivakor expects this model to provide several advantages, including: (i) a more efficient research and development process; (ii) a quicker time to market after completion of development; and (iii) the value-add growth to the hub company, Vivakor, through commercialization and subsidiary spin-off. Vivakor has commenced developing numerous products and currently has one pending utility patent. In October, 2008, it acquired a patented MRI software technology that it intends to develop. Vivakor generally intends to commercialize its products, after completion of development and any required regulatory approvals, primarily through one of three methods: (i) a sale of the technology; (ii) licensing of the product to a manufacturer or distributor or; (iii) by directly manufacturing, marketing and selling the products.

Product Research Divisions Vivakor's research efforts are divided into four primary areas of medical and biotechnological development. These are: 1. Molecular Medicine. The goal of this division centers on the development of biologically relevant molecules, tests and methods and their application in the practice of medicine.

Vivakor plans to translate systems biology (genomics, proteomics, metabalomics, etc.) insights of the molecular and cellular basis of disease into commercializable theranostic (diagnostic/therapeutic) products. Vivakor scientists will be participants in the discovery and development of new drugs and the early diagnosis of disease states.

The central aim of the molecular medicine division is cancer detection and wound healing, which we anticipate will lead to the development of customized treatments. Research in stem cell biology and nuclear reprogramming is a critical element in this research.

2. Electro-Optics. This division is charged with the development of biomedical and related consumer products that incorporate optical and electronic engineering. Vivakor has actively designed, built and tested several new electro-optic devices to reach previously un-served or underserved areas of the biomedical device market and believes the market potential during the first 12 months of commercialization of these products is over $15 million. Products scheduled for development in this area include: -- VivaSight: a digital photorefractor that is intended to modernize child vision screening. Approval has been granted from Western Institutional Review Board (20080731) to conduct human validation studies of the VivaSight technology on children. This study is currently being conducted at The University of Iowa Hospitals and Clinics.

-- Clinical Biomolecular Sensor (CBS): a label free multiplexed approach for use in the detection and diagnosis of complex human conditions (cancer, infectious diseases, cardiovascular disease, metabolic disorders, auto immune and inflammatory diseases)Multi-spectral Imaging: devices to examine burn degree and cutaneous melanoma and

-- Spectroscopic devices: to track wound healing and ear infection.

With the acquisition of HealthAmerica's SLICES(TM) technology, the Company plans to adapt and upgrade this technology to produce enhanced MRI images, which are expected to improve MRI resolution while providing additional data such as blood flow velocity in imaged tissues. The Company believes its potential market share for this product is over $300 million annually .

3. Biological Handling. Vivakor has developed commercial products for cryogengenic preservation, and storage through its VivaThermic Cryovials (USPTO Utility Patent # 12423998) which are currently being sold and have improved temperature control and were designed to improve cryopreservation and thawing of sensitive biological material. Vivakor expects that the market potential for its products is over $10 million over the next 12 months. It plans to continue to explore new techniques to improve methods and products employed for cryogenic preservation, storage and handling. Future research plans for this division include: -- stem cell specific improved cryovials; -- cryogenic devices for temperature maintenance and sample transport); -- a cryogenic biopsy device (Cryopsy); and

-- improved modular cryogenic freezer designs.

4. Natural and Formulary Products. This division plans to focus on the investigation, validation and adaptation of medical herbalism or botanical medicine. The Company has already developed a series of nutraceutical formulations, including VivaBlend, and plan to develop additional nutraceuticals, botanicals and supplements. Vivakor recently received a 25,000 unit purchase order for one of our products from Regeneca, International. Future products for this division include: -- fruit and vegetable extract for the protection of digestive system -- fresh fruit and vegetable extract for antioxidant supplements; and

-- jam and jelly formula to contain both antioxidant supplements as well as bone & cartilage supplements for healthy joints

More information can be found about Vivakor at www.vivakor.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com
e-mail: info@StockMarketingInc.com
Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (ACTC) ACTC. (ACTC) has Short Term PowerRatings at TradingMarkets. Details on (ACTC) Short Term PowerRatings is available at This Link.

For full details on (MNDP) MNDP. (MNDP) has Short Term PowerRatings at TradingMarkets. Details on (MNDP) Short Term PowerRatings is available at This Link.

For full details on (SMID) SMID. (SMID) has Short Term PowerRatings at TradingMarkets. Details on (SMID) Short Term PowerRatings is available at This Link.

For full details on (PSGI) PSGI. (PSGI) has Short Term PowerRatings at TradingMarkets. Details on (PSGI) Short Term PowerRatings is available at This Link.

For full details on (ONCP) ONCP. (ONCP) has Short Term PowerRatings at TradingMarkets. Details on (ONCP) Short Term PowerRatings is available at This Link.

For full details on (VIVK) VIVK. (VIVK) has Short Term PowerRatings at TradingMarkets. Details on (VIVK) Short Term PowerRatings is available at This Link.